QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.106.118604v1 322/3/1294    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Sullivan, N. R. Articles by Jones, P. G. Search for Related Content PubMed PubMed Citation Articles by Sullivan, N. R. Articles by Jones, P. G.

NEUROPHARMACOLOGY

Pharmacological Characterization of the Muscarinic Agonist (3R,4R)-3-(3-Hexylsulfanyl-pyrazin-2-yloxy)-1-aza-bicyclo[2.2.1]heptane (WAY-132983) in in Vitro and in Vivo Models of Chronic Pain

Neuroscience Discovery Research, Wyeth Research, Princeton, New Jersey

Here, we have investigated the in vitro pharmacology of a muscarinic agonist, (3R,4R)-3-(3-hexylsulfanyl-pyrazin-2-yloxy)-1-aza-bicyclo[2.2.1]heptane (WAY-132983), and we demonstrated its activity in several models of pain. WAY-132983 had a similar affinity for the five muscarinic receptors (9.4–29.0 nM); however, in calcium mobilization studies it demonstrated moderate selectivity for M₁ (IC₅₀ = 6.6 nM; E_max = 65% of 10 µM carbachol-stimulation) over the M₃ (IC₅₀ = 23 nM; E_max = 41%) and M₅ receptors (IC₅₀ = 300 nM; E_max = 18%). WAY-132983 also activated the M₄ receptor, fully inhibiting forskolin-induced increase in cAMP levels (IC₅₀ = 10.5 nM); at the M₂ receptor its potency was reduced by 5-fold (IC₅₀ = 49.8 nM). In vivo, WAY-132983 demonstrated good systemic bioavailability and high brain penetration (>20-fold over plasma levels). In addition, WAY-1329823 produced potent and efficacious antihyperalgesic and antiallodynic effects in rodent models of chemical irritant, chronic inflammatory, neuropathic, and incisional pain. It is noteworthy that efficacy in these models was observed at doses that did not produce analgesia or ataxia. Furthermore, a series of antagonist studies demonstrated that the in vivo activity of WAY-132983 is mediated through activation of muscarinic receptors primarily through the M₄ receptor. The data presented herein suggest that muscarinic agonists, such as WAY-132983, may have a broad therapeutic efficacy for the treatment of pain.

Address correspondence to: Dr. Nicole R. Sullivan, Neuroscience Discovery Research, Wyeth Research, CN8000, Princeton, NJ 08543. E-mail: sullivan{at}wyeth.com